IRWD: Ironwood Pharma Company Short-Term Debt

Symbol and logo of brand Ironwood Pharma (IRWD)

The price action of Ironwood Pharmaceuticals (IRWD) allows for an analysis of short-term debt obligations, which currently stand at 0.00. The business relies on developing high-demand therapies for gastrointestinal organs. Strong confidence from physicians and patients confirms its status as an industry leader. The growth strategy is based on a combination of direct sales and the aggressive acquisition of promising molecules and startups.

IRWD (ironwoodpharma.com) Company Short-Term Debts history from 07/04/2022 to 11/01/2026

Analytical breakdowns for Ironwood Pharmaceuticals

- current quotes and average value forecast:
Price Chart Ironwood Pharmaceuticals Inc|IRWD - Fair Value Consensus
- market capitalization information:
Market Value Ironwood Pharmaceuticals, Inc.|IRWD - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Ironwood Pharmaceuticals|IRWD - Book Capitalization|Market Cap to Net Assets Ratio ironwoodpharma.com|IRWD - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Ironwood Pharmaceuticals|IRWD - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Ironwood Pharmaceuticals Inc|IRWD - Company Total Debt Obligations|Debt to Book Value Ironwood Pharmaceuticals, Inc.|IRWD - Amount of Long-Term Liabilities|Company Short-Term Debts Ironwood Pharmaceuticals|Quick Liquidity ironwoodpharma.com
- net income and valuation multiples indicators:
IRWD - Final Profit
Fundamental company analysis:ironwoodpharma.com - IRWD
Manufactured products of Ironwood Pharma

Stable royalties from gastrointestinal drug sales provide Ironwood Pharmaceuticals (IRWD) with a predictable cash flow. By analyzing short-term debt volume, an investor assesses the total liabilities maturing within one year. This metric measures liquidity by comparing current debts against available current assets. A reduction in this indicator minimizes refinancing risks. Such financial discipline confirms the high reliability of the asset.

Who Ironwood Pharmaceuticals competes with

PHAT - Company Short-Term Debt|Company Short-Term Loans and Borrowings TERN (Terns Pharma)|curanexpharma.com (CURX) - Company Short-Term Debt|Company Current Liabilities Immuron|EVOK (Evoke Pharma, Inc.) - Company Short-Term Debts|Company Short-Term Debts Entero|Company Current Liabilities RDHL (RedHill Biopharma)|PALI (palisadebio.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts JAGX (Jaguar Animal Health)|Short-Term Indebtedness Biora Therapeutics, Inc|Morphic Holding, Inc. - Company Short-Term Debts